According to filings with the U.S. Securities and Exchange Commission, SonoThera has raised $125,000,000.00 in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Waterman Ventures, Northwestern Medicine Innovation Fund, Else Krner-Fresenius-Stiftung, OrbiMed, Deerfield Management, GV, ARCH Venture Partners, DCVC, Ji Xing Pharmaceuticals, Alexandria Venture Investments.

About SonoThera
SonoThera is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy using a proprietary, ultrasound-mediated delivery (UMD) platform. Through this nonviral, non-invasive approach, the company is developing next-generation genetic medicines that enable broad, highly targeted biodistribution to nearly any organ while avoiding unwanted off-target delivery and the immunogenicity and toxicity associated with viral and traditional nonviral vectors. The company is advancing therapeutic programs across multiple organ systems, including muscle, kidney, liver, heart, adipose tissue, and the central nervous system, with publicly presented data in diseases such as Duchenne muscular dystrophy, limb-girdle muscular dystrophies, X-linked Alport Syndrome, and autosomal dominant polycystic kidney disease, and is planning to initiate its first human clinical trial in 2027 with several additional INDs to follow. Headquartered in South San Francisco, California, SonoThera has also bolstered its position with a $60.75 million Series A financing to further optimize its platform, expand preclinical development, and establish in-house capabilities for advanced payload design, engineering, and manufacturing across multiple genetic modalities.

To learn more, visit https://sonothera.com/
Linkedin: https://www.linkedin.com/company/sonothera/

Contact:
Kenneth Greenberg, Chief Executive Officer
https://www.linkedin.com/in/kenneth-greenberg-55441215/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.